GlassScriptPhysician profile
Obiefuna C Okoli
NPI 1457560492
$12,297.64
in general payments reported to CMS, 2019-2025
23 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $853 · 2021: $1,610 · 2022: $2,155 · 2023: $2,414 · 2024: $1,868 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,040 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,039.91 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,285.44 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,127.44 | 2019-2025 | Epclusa, Veklury, Biktarvy |
| Abbvie INC. | $1,537.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,501.85 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Allergan, INC. | $758.46 | 2019-2020 | |
| Janssen Biotech, INC. | $499.22 | 2019-2023 | Symtuza |
| Insmed, INC. | $399.73 | 2022-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $356.66 | 2019-2024 | Cresemba |
| Janssen Products, LP | $214.98 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $152.77 | 2023-2024 | Symtuza |
| Ferring Pharmaceuticals INC. | $98.34 | 2022-2023 | Rebyota |
| La Jolla Pharmaceutical Company | $80.67 | 2025 | Zevtera, Xacduro |
| Paratek Pharmaceuticals, INC. | $48.89 | 2025 | Nuzyra |
| Abiomed | $46.24 | 2025 | |
| Napo Pharmaceuticals INC | $34.63 | 2025 | Mytesi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Redhill Biopharma INC. | $22.97 | 2022 | |
| Boston Scientific Corporation | $22.81 | 2025 | Watchman Access System |
| Pfizer INC. | $17.61 | 2025 | |
| Grifols USA, LLC | $17.25 | 2023 | Xembify |
| Eisai INC. | $17.22 | 2021 | |
| Nabriva Therapeutics, Plc | $15.50 | 2020 | |
| Glaxosmithkline, LLC. | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obiefuna Okoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.